Lilly, Dicerna to collaborate on RNAi research for several targets
Eli Lilly and Company (Lilly) and Dicerna Pharmaceuticals have signed a global licensing and research collaboration focused on the discovery, development and commercialization of new drugs in the areas of cardio-metabolic disease, neurodegeneration and pain.